2024

The company accepted third-party verification of ISO 14064-1 greenhouse gas emissions and removal by Gray International Verification Company on October 21st and 25th, and obtained a third-party verification statement on November 8th.

Announcement that our company's product Leuprolide Acetate Injection has obtained the US ANDA drug license approval.

The company's expanded factory's sterile injection (sterile vial line-2) has passed the GMP inspection of Taiwan's Ministry of Health and Welfare.

The company underwent an on-site review by the TTQS assessment committee on September 11, 2024, and was notified on September 20 that the company passed the TTQS talent development quality management system assessment (enterprise organization version) and obtained the bronze medal certification, which affirms the company's The quality and ability of company training.

Our company's "Single-Chain Immunoglobulin Fusion Protein Technology Platform" has been approved by the European Patent Office. This technology is applied to our proprietary product UB-853 and has already obtained patents in the United States, China, Japan, Taiwan, India, Australia, Malaysia, Singapore, Canada, and Hong Kong. Patent applications are currently under review in South Korea, New Zealand, and Brazil.

Our company has passed the GMP inspection conducted by the UK MHRA, with the inspection report indicating no significant deficiencies. The result of the report is "compliant."